Zetagen Announces the Appointment of Debasish (Debu) Tripathy M.D. to its Advisory Board
March 18, 2024, (Syracuse, New York) – Zetagen Therapeutics, a private, clinical-stage, biopharmaceutical company dedicated to developing breakthrough therapies via local administration for the treatment of metastatic and primary cancers in bone and soft tissue organs, today announced the appointment of Debasish (Debu) Tripathy, MD to its advisory board. Dr. Tripathy is Professor and Chairman, Department of Breast Medical Oncology, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center.